Oxford scientists expect some vaccine data on UK mutant virus by next week
(Reuters) - The University of Oxford expects efficacy data on a study of its COVID-19 vaccine against the UK variant of the coronavirus by next week, a representative said on Wednesday at a virtual meeting of a U.S. CDC advisory panel
(Reuters) - The University of Oxford expects efficacy data on a study of its COVID-19 vaccine against the UK variant of the coronavirus by next week, a representative said on Wednesday at a virtual meeting of a U.S. CDC advisory panel.
"Since the middle of December, that (UK) variant has been dominant and spread so rapidly. And so, we should be able to put together an analysis on efficacy against that probably by next week," said Andrew Pollard, director of the Oxford Vaccine Group and chief investigator of the trials.
Oxford University has developed the vaccine along with AstraZeneca.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Saumyadeb Chakrabarty)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Subscribe to Moneycontrol Pro at ₹499 for the first year. Use code PRO499. Limited period offer. *T&C apply
By John McCrank NEW YORK (Reuters) - Robinhood, the online brokerage used by many retail traders to pile in to heavily shorted stocks like GameStop Corp, has made an ambitious push into loaning out its clients' shares to short sellers as it expands its business. The broker had $1.9 billion in shares loaned out as of Dec. 31, nearly three times the $674 million a year earlier, and it was permitted to lend out $4.6 billion worth of securities under margin agreements, around five times bigger than the prior year, according to an annual regulatory filing late on Monday
By Pete Schroeder and Chris Prentice WASHINGTON (Reuters) - U.S. President Joe Biden's pick to head a key market regulator promised on Tuesday a thorough review of issues raised by the GameStop Corp stock frenzy and suggested companies may have to disclose their potential risks from climate change